The translational potential of microRNAs as biofluid markers of urological tumours
- PMID: 27804986
- DOI: 10.1038/nrurol.2016.193
The translational potential of microRNAs as biofluid markers of urological tumours
Abstract
MicroRNAs (miRNAs) are secreted by cells in vesicles, bound in a ribonucleoprotein complex or as free molecules. These miRNA secretion pathways are dysregulated in cancer, making miRNAs attractive candidate molecules for liquid biopsies. A number of studies have investigated the regulation of miRNA secretion into blood and urine and suggested that miRNAs are noninvasive diagnostic, prognostic and surveillance markers in urological carcinomas, and research in this area has increased over the past 5 years. However, methodological and analytical pitfalls exist and require addressing to enable future translation of the laboratory findings regarding miRNAs as biomarkers into clinical practice in bladder cancer, kidney cancer, prostate cancer and testicular cancer.
Similar articles
-
[MicroRNAs as potential noninvasive markers in the diagnosis of urological malignancies].Urologiia. 2016 Apr;(2):96-102. Urologiia. 2016. PMID: 28247670 Russian.
-
MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors.Crit Rev Oncog. 2013;18(4):289-302. doi: 10.1615/critrevoncog.2013007176. Crit Rev Oncog. 2013. PMID: 23614616 Review.
-
Urine microRNAs as potential noninvasive biomarkers in urologic cancers.Urol Oncol. 2014 Jan;32(1):41.e1-9. doi: 10.1016/j.urolonc.2013.04.011. Epub 2013 Sep 10. Urol Oncol. 2014. PMID: 24035473 Review.
-
Epigenetic biomarkers in the blood of patients with urological malignancies.Expert Rev Mol Diagn. 2015 Apr;15(4):505-16. doi: 10.1586/14737159.2015.1019477. Epub 2015 Feb 26. Expert Rev Mol Diagn. 2015. PMID: 25719388 Review.
-
MicroRNAs and cancer: current state and future perspectives in urologic oncology.Urol Oncol. 2010 Jan-Feb;28(1):4-13. doi: 10.1016/j.urolonc.2008.10.021. Epub 2008 Dec 30. Urol Oncol. 2010. PMID: 19117772 Review.
Cited by
-
Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update.Cancers (Basel). 2022 Jun 28;14(13):3157. doi: 10.3390/cancers14133157. Cancers (Basel). 2022. PMID: 35804929 Free PMC article. Review.
-
Holding a MIRror up to the robustness of the prostate cancer urinary transcriptome.Transl Androl Urol. 2019 Dec;8(Suppl 5):S488-S490. doi: 10.21037/tau.2019.09.25. Transl Androl Urol. 2019. PMID: 32042627 Free PMC article. No abstract available.
-
miR-491-5p, mediated by Foxi1, functions as a tumor suppressor by targeting Wnt3a/β-catenin signaling in the development of gastric cancer.Cell Death Dis. 2017 Mar 30;8(3):e2714. doi: 10.1038/cddis.2017.134. Cell Death Dis. 2017. PMID: 28358374 Free PMC article.
-
Small nucleolar RNAs signature (SNORS) identified clinical outcome and prognosis of bladder cancer (BLCA).Cancer Cell Int. 2020 Jul 10;20:299. doi: 10.1186/s12935-020-01393-7. eCollection 2020. Cancer Cell Int. 2020. PMID: 32669975 Free PMC article.
-
MicroRNAs: Key Players in Bladder Cancer.Mol Diagn Ther. 2019 Oct;23(5):579-601. doi: 10.1007/s40291-019-00410-4. Mol Diagn Ther. 2019. PMID: 31325035 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous